Drug Trial Radar · NCT04417530
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Last checked: Nov 19, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Aug 5, 2020
Primary completion
Apr 22, 2024
Study completion Apr 22, 2024
Sponsor
- Lead sponsor
- Aura BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Jun 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
Conditions
- Uveal Melanoma
- Ocular Melanoma
- Choroidal Melanoma
Interventions
AU-011Drug
AU-011 Via Suprachoroidal Administration
Suprachoroidal MicroinjectorDevice
Suprachoroidal Injection Device
PDT LaserDevice
Laser Administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment related AEs and treatment related serious adverse events (SAEs).Time frame: 52 weeks
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Retina Associates SW, P.C.
Tucson, Arizona
UCLA Jules Stein Eye Institute
Los Angeles, California
Byers Eye Institute at Stanford University
Palo Alto, California
UCHealth Eye Center
Aurora, Colorado
Retina Associates of Florida
Tampa, Florida
Emory Eye Center
Atlanta, Georgia
University of Illinois At Chicago Illinois Eye and Ear Infirmary
Chicago, Illinois
Midwest Eye Institute
Carmel, Indiana
University of Iowa Department of Ophthalmology and Visual Sciences
Iowa City, Iowa
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts
W. K. Kellogg Eye Center, University of Michigan
Ann Arbor, Michigan
Associated Retinal Consultants, PC
Royal Oak, Michigan
Retina Center
Minneapolis, Minnesota
Columbia University Medical Center
New York, New York
Dean McGee Eye Institute
Oklahoma City, Oklahoma
Oregon Health & Science University Casey Eye Institute
Portland, Oregon
Wills Eye Hospital
Philadelphia, Pennsylvania
Retina Consultants of Carolina, PA
Greenville, South Carolina
St. Thomas Health / Tennessee Retina, PC
Nashville, Tennessee
Texas Retina Associates
Dallas, Texas
Retina Consultants of Houston
Houston, Texas
University of Wisconsin Dept of Ophthalmology & Visual Sciences
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.